As reported by Kaiser Health News: The value of drugmakers’ copay cards has become more unpredictable as insurers try to restrict their use. Many insurance plans, for instance, do not count the money from a copay program toward a patient’s deductible.And patients who use a copay card can wind up paying full or nearly full price…
Oren Nissim is the CEO of Brook-ai which is been making some waves in the remote care space. Their goals is to use remote patient monitoring to help providers reduce readmissions, and help patients stay on their care plans. For example they get more then 50% of their populations into hypertension control within 10 weeks,…
Grow Therapy’s Series D funding was led by TCV and Growth Equity at Goldman Sachs Alternatives, with participation from BCI, Menlo Ventures, Sequoia, SignalFire and Transformation Capital. The post Grow Therapy Raises $150M to Expand Employer, Health System Partnerships appeared first on MedCity News.
The new funding will accelerate product development, AI automation, and expansion across various behavioral health settings
Ampreloxetine’s Phase 3 failure in multiple system atrophy is the third disappointing clinical trial outcome for the Theravance Biopharma drug. The biotech will now wind down all R&D and explore options that could include the sale of the company. The post Theravance Drug Fails Another Pivotal Test, This Time Sparking Restructuring That Ends R&D appeared…
Last week, Trump proposed cutting out insurers and giving Americans cash to buy their own healthcare, claiming it would lower costs. Ali Diab, an economist and CEO of Collective Health, said the plan overlooks the real problem: concentrated payer power, opaque pricing and the financial risk people face without insurance. The post Why Trump’s ‘Cash…
This updated fact sheet provides the latest data on the global HIV/AIDS epidemic, including impact on affected and vulnerable populations, treatment and prevention efforts, and an overview of the U.S. and global responses to the epidemic.
The Medicare Part D prescription drug benefit is provided by private plans, either Medicare Advantage plans that offer drug coverage (MA-PDs) or, for those in traditional Medicare, stand-alone prescription drug plans (PDPs). New data from CMS shows that 56 million people are enrolled in Part D plans as of February 2026, with more in MA-PDs…
For providers, the rules mean more control over monitoring and the chance to keep a larger share of reimbursement. For device companies, they create a chance to show measurable value and guide clinicians through a system that is shifting quickly. The post How New Medicare Rules Will Reshape Cardiac Monitoring and Remote Patient Care appeared…
When healthcare delivery strategies shifted to the home out of necessity during the pandemic, healthcare consumers began to question the value of navigating the old system, one that requires time off work, transportation, childcare, and long waits just to have basic needs met. The post Healthcare At Your Door Is Now The Expectation. There’s No…